15 USD
+1.07 (+7.68%)
At close: Feb 11, 2026
15 USD
0 (0%)
After Hours: 2/11/2026, 4:56:36 PM
Taking everything into account, SGRY scores 3 out of 10 in our fundamental rating. SGRY was compared to 102 industry peers in the Health Care Providers & Services industry. While SGRY is still in line with the averages on profitability rating, there are concerns on its financial health. SGRY is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year SGRY was profitable.
- SGRY had a positive operating cash flow in the past year.
- In the past 5 years SGRY always reported negative net income.
- In the past 5 years SGRY always reported a positive cash flow from operatings.
1.2 Ratios
- SGRY's Return On Assets of -2.16% is in line compared to the rest of the industry. SGRY outperforms 41.18% of its industry peers.
- Looking at the Return On Equity, with a value of -9.94%, SGRY is in line with its industry, outperforming 44.12% of the companies in the same industry.
- SGRY's Return On Invested Capital of 5.57% is in line compared to the rest of the industry. SGRY outperforms 59.80% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for SGRY is below the industry average of 9.04%.
- The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.57%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROIC | 5.57% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
- SGRY has a better Operating Margin (15.78%) than 93.14% of its industry peers.
- SGRY's Operating Margin has been stable in the last couple of years.
- Looking at the Gross Margin, with a value of 26.57%, SGRY is in line with its industry, outperforming 55.88% of the companies in the same industry.
- SGRY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
- SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for SGRY has been increased compared to 1 year ago.
- The number of shares outstanding for SGRY has been increased compared to 5 years ago.
- Compared to 1 year ago, SGRY has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.74, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.74, SGRY is doing worse than 72.55% of the companies in the same industry.
- The Debt to FCF ratio of SGRY is 18.37, which is on the high side as it means it would take SGRY, 18.37 years of fcf income to pay off all of its debts.
- SGRY has a Debt to FCF ratio of 18.37. This is comparable to the rest of the industry: SGRY outperforms 41.18% of its industry peers.
- SGRY has a Debt/Equity ratio of 2.00. This is a high value indicating a heavy dependency on external financing.
- SGRY has a Debt to Equity ratio of 2.00. This is in the lower half of the industry: SGRY underperforms 73.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Altman-Z | 0.74 |
ROIC/WACC0.63
WACC8.78%
2.3 Liquidity
- SGRY has a Current Ratio of 1.88. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
- SGRY has a Current ratio of 1.88. This is in the better half of the industry: SGRY outperforms 78.43% of its industry peers.
- SGRY has a Quick Ratio of 1.72. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
- With a decent Quick ratio value of 1.72, SGRY is doing good in the industry, outperforming 72.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
- SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
- The Revenue has grown by 10.14% in the past year. This is quite good.
- Measured over the past years, SGRY shows a quite strong growth in Revenue. The Revenue has been growing by 11.20% on average per year.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
- The Earnings Per Share is expected to grow by 12.89% on average over the next years. This is quite good.
- SGRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.88% yearly.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 19.23, SGRY is valued on the expensive side.
- Compared to the rest of the industry, the Price/Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 77.45% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of SGRY to the average of the S&P500 Index (28.23), we can say SGRY is valued slightly cheaper.
- A Price/Forward Earnings ratio of 20.01 indicates a rather expensive valuation of SGRY.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 64.71% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.01. SGRY is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.23 | ||
| Fwd PE | 20.01 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, SGRY is valued a bit cheaper than the industry average as 78.43% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of SGRY indicates a rather cheap valuation: SGRY is cheaper than 87.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10 | ||
| EV/EBITDA | 8.02 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
5. Dividend
5.1 Amount
- No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15
+1.07 (+7.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners80.81%
Inst Owner Change1.01%
Ins Owners1.11%
Ins Owner Change0.05%
Market Cap1.94B
Revenue(TTM)3.29B
Net Income(TTM)-171.90M
Analysts81.11
Price Target25.96 (73.07%)
Short Float %20.04%
Short Ratio9.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-2.1%
PT rev (3m)-18.41%
EPS NQ rev (1m)-5.17%
EPS NQ rev (3m)-38.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.86%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-6.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.23 | ||
| Fwd PE | 20.01 | ||
| P/S | 0.59 | ||
| P/FCF | 10 | ||
| P/OCF | 6.88 | ||
| P/B | 1.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.02 |
EPS(TTM)0.78
EY5.2%
EPS(NY)0.75
Fwd EY5%
FCF(TTM)1.5
FCFY10%
OCF(TTM)2.18
OCFY14.53%
SpS25.42
BVpS13.37
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROCE | 7.05% | ||
| ROIC | 5.57% | ||
| ROICexc | 5.57% | ||
| ROICexgc | 18.41% | ||
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% | ||
| FCFM | 5.9% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Debt/EBITDA | 5.17 | ||
| Cap/Depr | 58.56% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | 0.74 |
F-Score4
WACC8.78%
ROIC/WACC0.63
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y15.88%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y18.25%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
What is the valuation status for SGRY stock?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
What is the financial health of SURGERY PARTNERS INC (SGRY) stock?
The financial health rating of SURGERY PARTNERS INC (SGRY) is 2 / 10.
What is the earnings growth outlook for SURGERY PARTNERS INC?
The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -29.92% in the next year.